COMPLETED

Phenylephrine Versus Eyelid Taping for Muller's Muscle-Conjunctival Resection (MMCR) Evaluation

Talk to us

Conditions

Ptosis, Eyelid

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This research study aims to compare whether Phenylephrine 2.5% ophthalmic eye drop solution can serve as a better indicator of the effect of a drooping upper eyelid (ptosis) by covering part of the upper portion of the field of vision as compared to traditional use of tape to lift up the upper eyelid in the evaluation of patients for surgical upper eyelid repair.

Official Title

Phenylephrine Versus Upper Eyelid Taping For Muller's Muscle Conjunctival Resection Evaluation

Quick Facts

Study Start:2024-03-19
Study Completion:2025-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05890027

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Individuals diagnosed with ptosis undergoing conjunctival Muller's muscle resection evaluation.
  2. * Individuals who can tolerate and have no hypersensitivity to phenylephrine 2.5% ophthalmic solution.
  3. * Individuals who can tolerate eye-drop medications.
  4. * Individuals who are physically able to take a tangent screen visual field test.
  5. * Age: Adults who can comprehend the instructions and procedures (18+ years old)
  1. * This study will not include participants who refuse to consent.
  2. * This study will not include participants who are too tired or unable to take a tangent screen visual field test (see Risk to Subjects).
  3. * This study will not include individuals who may not be able to tolerate phenylephrine 2.5% ophthalmic solution.
  4. * Specifically, those with a past medical history of bradycardia, hypotension, autonomic dysfunction, or severe cardiovascular disease
  5. * This study will not include individuals who consume drugs contraindicated in phenylephrine use: Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates), Iobenguane Radiopharmaceutical Products, Kratom, Lisuride, Monoamine Oxidase Inhibitors

Contacts and Locations

Principal Investigator

Sara T Wester, MD
PRINCIPAL_INVESTIGATOR
University of Miami

Study Locations (Sites)

University of Miami Bascom Palmer Eye Institute
Miami, Florida, 33136
United States

Collaborators and Investigators

Sponsor: University of Miami

  • Sara T Wester, MD, PRINCIPAL_INVESTIGATOR, University of Miami

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-19
Study Completion Date2025-04-01

Study Record Updates

Study Start Date2024-03-19
Study Completion Date2025-04-01

Terms related to this study

Additional Relevant MeSH Terms

  • Ptosis, Eyelid